Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Blood Cells, Molecules & Diseases
|
August 17, 2014
DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)
Gemma E Logan, Nirit Mor-Vaknin, Till Braunschweig, et al.
Arthritis and Rheumatism
|
February 1, 2011
DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen
Nirit Mor-Vaknin, Ferdinand Kappes, Amalie E Dick, et al.
Frontiers in Immunology
|
January 31, 2020
Citrullinated Histone H3 as a Therapeutic Target for Endotoxic Shock in Mice
Qiufang Deng, Baihong Pan, Hasan B Alam, et al.
Plos One
|
September 23, 2016
Vimentin, a Novel NF-κB Regulator, Is Required for Meningitic Escherichia coli K1-Induced Pathogen Invasion and PMN Transmigration across the Blood-Brain Barrier
Sheng-He Huang, Feng Chi, Liang Peng, et al.
Molecular and Cellular Biology
|
October 13, 2006
The DEK nuclear autoantigen is a secreted chemotactic factor
Nirit Mor-Vaknin, Antonello Punturieri, Kajal Sitwala, et al.
Chemistry & Biology
|
June 23, 2007
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
Paola Bargagna-Mohan, Adel Hamza, Yang-eon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2013
Intercellular trafficking of the nuclear oncoprotein DEK
Anjan K Saha, Ferdinand Kappes, Amruta Mundade, et al.
The Journal of Clinical Investigation
|
May 21, 2019
Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling
Maegan L Capitano, Nirit Mor-Vaknin, Anjan K Saha, et al.
Lupus
|
March 29, 2020
Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis
Andrew J Kinloch, Matthew D Cascino, Jian Dai, et al.
Nature Microbiology
|
August 31, 2016
Intermediate filaments enable pathogen docking to trigger type 3 effector translocation
Brian C Russo, Luisa M Stamm, Matthijs Raaben, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Blood Cells, Molecules & Diseases
|
August 17, 2014
DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)
Gemma E Logan, Nirit Mor-Vaknin, Till Braunschweig, et al.
Arthritis and Rheumatism
|
February 1, 2011
DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen
Nirit Mor-Vaknin, Ferdinand Kappes, Amalie E Dick, et al.
Frontiers in Immunology
|
January 31, 2020
Citrullinated Histone H3 as a Therapeutic Target for Endotoxic Shock in Mice
Qiufang Deng, Baihong Pan, Hasan B Alam, et al.
Plos One
|
September 23, 2016
Vimentin, a Novel NF-κB Regulator, Is Required for Meningitic Escherichia coli K1-Induced Pathogen Invasion and PMN Transmigration across the Blood-Brain Barrier
Sheng-He Huang, Feng Chi, Liang Peng, et al.
Molecular and Cellular Biology
|
October 13, 2006
The DEK nuclear autoantigen is a secreted chemotactic factor
Nirit Mor-Vaknin, Antonello Punturieri, Kajal Sitwala, et al.
Chemistry & Biology
|
June 23, 2007
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
Paola Bargagna-Mohan, Adel Hamza, Yang-eon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 10, 2013
Intercellular trafficking of the nuclear oncoprotein DEK
Anjan K Saha, Ferdinand Kappes, Amruta Mundade, et al.
The Journal of Clinical Investigation
|
May 21, 2019
Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling
Maegan L Capitano, Nirit Mor-Vaknin, Anjan K Saha, et al.
Lupus
|
March 29, 2020
Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis
Andrew J Kinloch, Matthew D Cascino, Jian Dai, et al.
Nature Microbiology
|
August 31, 2016
Intermediate filaments enable pathogen docking to trigger type 3 effector translocation
Brian C Russo, Luisa M Stamm, Matthijs Raaben, et al.
Page
of 3